RABL2A: A Potential Drug Target and Biomarker for Cancer (G11159)

Target Name: RABL2A

NCBI ID: G11159

RABL2A

RABL2A: A Potential Drug Target and Biomarker for Cancer

Ras (Ras-related gene 2) is a family of proteins that are involved in cell signaling pathways, including cell proliferation, survival, and angiogenesis. RABL2A, a member of the RAS oncogene family like 2A, is a gene that has been identified as a potential drug target and biomarker for cancer.

The RAS oncogene family includes four genes: RAB1, RAB2, RAB3, and RABL2A. RAB1 and RAB2 are involved in the production of poly(ADP-ribose) polymerase (PARP), a protein that helps regulate DNA repair. RAB3 is involved in the production of transforming growth factor beta (TGF-β), a protein that promotes cell growth and division. RABL2A is involved in the production of sonic hedgehog (SHH), a protein that is involved in cell signaling pathways, including cell proliferation and survival.

RABL2A is a 21-kDa protein that is expressed in a variety of tissues, including brain, heart, liver, and cancer. It is a key regulator of SHH signaling, and its levels have been shown to be elevated in a variety of cancer types, including lung, breast, and colorectal cancer.

Sonic hedgehog (SHH) is a small G protein that is involved in the development and maintenance of tissues, including organs and tissues. It is a key regulator of cell proliferation, and is involved in the formation of tissues during development. SHH signaling is also involved in the regulation of pain perception and neurogenesis.

RABL2A has been shown to be involved in the regulation of SHH signaling in a variety of contexts. For example, studies have shown that RABL2A is involved in the regulation of SHH signaling in the development and maintenance of the neural stem cell, and that it plays a role in the regulation of neuron growth and differentiation.

In addition to its role in SHH signaling, RABL2A has also been shown to be involved in the regulation of cell survival and proliferation. Studies have shown that RABL2A is involved in the regulation of cell survival and proliferation in a variety of contexts, including in the regulation of cell cycle progression and in the inhibition of apoptosis.

Given its involvement in SHH signaling and its potential role in cell survival and proliferation, RABL2A is a promising drug target and biomarker for cancer. Studies have shown that inhibiting RABL2A activity can lead to the inhibition of SHH signaling and the growth and survival of cancer cells. In addition, RABL2A has been shown to be expressed in a variety of cancer types, making it a potential biomarker for cancer diagnosis and treatment.

In conclusion, RABL2A is a protein that has been identified as a potential drug target and biomarker for cancer. Its involvement in SHH signaling and its potential role in cell survival and proliferation make it a promising target for cancer treatment. Further studies are needed to fully understand the role of RABL2A in cancer biology and to develop effective treatments.

Protein Name: RAB, Member Of RAS Oncogene Family Like 2A

Functions: Plays an essential role in male fertility, sperm intra-flagellar transport, and tail assembly. Binds, in a GTP-regulated manner, to a specific set of effector proteins including key proteins involved in cilia development and function and delivers them into the growing sperm tail

The "RABL2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RABL2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets